AzTrials
AzTrials

Rett SyndromePhase 3NCT06840496

To Investigate the Efficacy of Treatment With Oral NA-921 (Bionetide) Versus Placebo in Females With Rett Syndrome

A Phase 3 study testing Bionetide in people with Rett Syndrome, run by Biomed Industries, Inc. at 18 sites in 2 countries.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Primary Objective • To investigate the efficacy of treatment with oral Bionetide versus placebo in girls and women with Rett syndrome Key Secondary Objective To investigate the efficacy of treatment with oral Bionetide versus placebo on ability to communicate in girls and women with Rett syndrome Read more about this study

Who is it for?
Ages 5 to 20 years, women only
Conditions the study is for
Rett Syndrome
What is being tested?
Bionetide
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
210 participants
Where
18 sitesin 2 countries
Study dates
30 Sep 2026to 30 Dec 2027
Phase
Phase 3
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 5 to 20 years
  • Women only
  • No healthy volunteers
  • Child, Adult

Who may be able to join

  • Female subjects 5 to 20 years of age, inclusive, at Screening
  • Body weight ≥12 kg at Screening
  • Can swallow the study medication provided as a liquid solution or can take it by gastrostomy tube
  • Has classic/typical Rett syndrome (RTT)
  • Has a documented disease-causing mutation in the MECP2 gene
  • Has a stable pattern of seizures, or has had no seizures, within 8 weeks of Screening
Show all 9Show fewer
  • Subjects of childbearing potential must abstain from sexual activity for the duration of the study and for at least 30 days thereafter or must agree to use acceptable methods of contraception. Subject must not be pregnant or breastfeeding.
  • The subject's caregiver is English-speaking and has sufficient language skills to complete the caregiver assessments
  • Subject and caregiver(s) must reside at a location to which study drug can be delivered and have been at their present residence for at least 3 months prior to Screening

Who cannot join

  • Has been treated with insulin within 12 weeks of Baseline
  • Has current clinically significant cardiovascular, endocrine (such as hypo- or hyperthyroidism, Type 1 diabetes mellitus, or uncontrolled Type 2 diabetes mellitus), renal, hepatic, respiratory or gastrointestinal disease (such as celiac disease or inflammatory bowel disease) or has major surgery planned during the study
  • Has a history of, or current, cerebrovascular disease or brain trauma
  • Has significant, uncorrected visual or uncorrected hearing impairment
  • Has a history of, or current, malignancy
  • Has a known history or symptoms of long QT syndrome

Trial locations and contacts

18 sites in 2 countries. Contact the study team or a site near you to ask about taking part.

David L Nguyen, PhD contact

1-800-824-5135

research@biomedind.com

Jennifer Thomposn, MS contact

1-800-824-5135

research@biomedind.com

18 sites in 2 countries

United States14 sites, 14 recruiting
  • Biomed Testing Facility #BIO-06-80042

    Aurora, Colorado, 80042

    Jennifer Thompson, MS, 8008245135, research@biomedind.com

    Michael Willis, MS, 8008245135, research@biomedind.com

    Recruiting
  • Maryland Locations Biomed Testing Facility #BIO-9-21205

    Baltimore, Maryland, 21205

    Jennifer Thompson, MS, 8008245135, research@biomedind.com

    8008245135, research@biomedind.com

    Recruiting
  • Biomed Testing Facility #BIO-10-02115

    Boston, Massachusetts, 02115

    Jennifer Thompson, MS, 8008245135, research@biomedind.com

    Michael Willis, MS, 8008245135, research@biomedind.com

    Recruiting
  • Biomed Testing Facility #BIO-08-60612

    Chicago, Illinois, 60612

    Jennifer Thompson, MS, 8008245135, research@biomedind.com

    Michael Willis, MS, 8008245135, research@biomedind.com

    Recruiting
  • Biomed Testing Facility #BIO-19-77030

    Houston, Texas, 77030

    Jennifer Thompson, MS, 8008245135, research@biomedind.com

    Michael Willis, MS, 8008245135, research@biomedind.com

    Recruiting
  • Biomed Testing Facility # BIO-05-92093

    La Jolla, California, 92093

    Jennifer Thompson, 8008245135, research@biomedind.com

    Michael Willis, 8008245135, research@biomedind.com

    Recruiting
  • Biomed Testing Facility # BIO-04-90095

    Los Angeles, California, 90045

    Jennifer Thompson, MS, 8008245135, research@biomedind.com

    Michael Willis, 8008245135, research@biomedind.com

    Recruiting
  • Biomed Testing Facility #BIO-17-19104

    Philadelphia, Pennsylvania, 19104

    Jennifer Thompson, MS, 8008245135, research@biomedind.com

    Michael Willis, MS, 8008245135, research@biomedind.com

    Recruiting
  • Biomed Testing Facility # BIO-01-85012

    Phoenix, Arizona, 85012

    Jennifer Thompson, MS, 8008245135, research@biomedind.com

    Michael Willis, MS, 8008245135, research@biomedind.com

    Recruiting
  • Biomed Testing Facility # BIO-03-95817

    Sacramento, California, 95817

    Jennifer Thompson, MS, 8008145135, research@biomedind.com

    Michael Willis, 8008245135, research@biomedind.com

    Recruiting
  • Biomed Testing Facility # BIO-02-94104

    San Francisco, California, 94104

    Jennifer Thompson, MS, 8008245135, research@biomedind.com

    Michael Willis, MS, 8008245135, research@biomedind.com

    Recruiting
  • Biomed Testing Facility #BIO-20-98105

    Seattle, Washington, 98105

    Jennifer Thompson, MS, 8008245135, research@biomedind.com

    Michael Willis, MS, 8008245135, research@biomedind.com

    Recruiting
  • Biomed Testing Facility #BIO-07-33606

    Tampa, Florida, 33606

    Jennifer Thompson, MS, 8008245135, research@biomedind.com

    Michael Willis, MS, 8008245135, research@biomedind.com

    Recruiting
  • Biomed Testing Facility #BIO-13-10467

    The Bronx, New York, 10467

    Jennifer Thompson, MS, 8008245135, research@biomedind.com

    Michael Willis, MS, 8008245135, research@biomedind.com

    Recruiting

Other trials in United States

Australia4 sites, 4 recruiting
  • Biomed Research Unit-BIO-23-NSW 2050

    Camperdown, New South Wales, 2050

    Jennifer Thompson, MS, 18008245135, research@biomedind.com

    Michael Willis, MS, 18008245135, research@biomedind.com

    Recruiting
  • Biomed Research Unit-BIO-21-VIC-3084

    Heidelberg West, Victoria, 3084

    Jennifer Thompson, MS, 18008245135, research@biomedind.com

    Michael Willis, MS, 18008245135, research@biomedind.com

    Recruiting
  • Biomed Research Unit- BIO-22-VIC 3010

    Parkville, Victoria, 3010

    Jennifer Thompson, MS, 18008245135, research@biomedind.com

    Michael Willis, 18008245135, research@biomedind.com

    Recruiting
  • Biomed Research Unit-BIO-24-NSW-4101

    South Brisbane, Queensland, 4101

    Jennifer Thompson, MS, 18008245135, research@biomedind.com

    Michael Willis, MS, 18008245135, research@biomedind.com

    Recruiting

Other trials in Australia

About this study

Official title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 3 Study of Bionetide for the Treatment of Girls and Women With Rett Syndrome

Primary Objective • To investigate the efficacy of treatment with oral Bionetide versus placebo in girls and women with Rett syndrome

Key Secondary Objective

  • To investigate the efficacy of treatment with oral Bionetide versus placebo on ability to communicate in girls and women with Rett syndrome
Read the detailed description

Co-Primary Endpoints

  • Rett Syndrome Behavior Questionnaire (RSBQ) total score - Change from Baseline to Week 12
  • Clinical Global Impression-Improvement (CGI-I) Score at Week 12

Key Secondary Endpoint

Change from Baseline to Week 12 in:

  • Communication and Symbolic Behavior Scales Developmental Profile™ Infant-Toddler Checklist- Social Composite Score (CSBS-DP-IT Social)
Conditions
Rett Syndrome
Being tested
Bionetide, Placebo
Keywords
Rett syndrome,, Genetic Diseases, X-Linked
Medical subject headings
Rett Syndrome, Genetic Diseases, X-Linked

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • BionetideDrug

    Also called NA-921

    Bionetide solution of 20-40 mL based on the subject's weight at Baseline, administered twice daily by mouth or gastrostomy tube (G-tube)

  • PlaceboDrug

    Also called Placebo of Bionedtide, NA-921 placebo

    Placebo

    • Bionetide placebo solution administered based on the subject's weight at Baseline, twice daily for 12 weeks
Study groups in NCT06840496
Study groupRoleWhat they receive
BionetideExperimentalExperimental: Bionetide Bionetide solution of 20-40 mL based on the subject's weight at Baseline, administered twice daily by mouth or gastrostomy tube (G-tube)
Receives: Drug: Bionetide
PlaceboPlacebo comparatorPlacebo: Bionetide placebo solution administered based on the subject's weight at Baseline, twice daily for 12 weeks
Receives: Drug: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Rett Syndrome Behavior Questionnaire (RSBQ) Total Score - Change From Baseline to Week 12

    The RSBQ is a 45-item caregiver-completed rating scale that includes 45 items, 39 of them grouped into 8 subscales, whose ratings reflect the severity and frequency of symptoms. Items are rated as 0 (not true), 1 (somewhat or sometimes true), or 2 (very true). The 8 subscales are general mood, breathing problems, hand behavior, face movements, body rocking/expressionless face, night-time behaviors, fear/anxiety, and walking/standing. Scores for item 31 are reversed in the calculation of the total score. The total score ranges from 0 to 90 and is calculated as the sum of the item scores. Higher scores mean worse behavior.

    Measured: Baseline and Week 12

  2. Clinical Global Impression-Improvement (CGI-I) Score at Week 12

    To rate how much the subject's illness has improved or worsened relative to a baseline state, a 7-point scale is used from 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse.

    Measured: 12 Weeks Treatment Duration

Secondary outcomes (9)
  1. Change From Baseline to Week 12 in Communication and Symbolic Behavior Scales Developmental

    Standardized screening scale for assessing communication and pre-linguistic skills in young children 12-24 months and can be used with older children with developmental delay. The CSBS-DP includes a suite of three separate measures: The Infant-Toddler Checklist, a follow-up Caregiver Questionnaire and a Behavior Sample. In this study only the Infant-Toddler (CSBS-DP-IT) Checklist was used. The CSBS-DP-IT Checklist is a 24-item rating scale and each item is scored using a three-level rating of frequency: "not yet", "sometimes" and "often". The CSBS-DP-IT Social Composite score the range was 0 to 26 and a higher score represented a worse outcome. Three composite scores can be calculated: 1) Social Composite; 2) Speech Composite; 3) Symbolic Composite.

    Measured: 12 Weeks Treatment Duration

  2. Change From Baseline to Week 12 in Impact of Childhood Neurologic Disability Scale (ICND) Total Score

    The Impact of Childhood Neurologic Disability (ICND) scale evaluates the effect of four conditions or health problems on 11 aspects of a child's or family's life as "A lot", "Some", "A little", "Not at all", or "Does not apply". The four conditions or health problems are 1) inattentiveness, impulsivity, or mood, 2) ability to think and remember, 3) neurologic or physical limitations, and 4) epilepsy. The ICND score the range of 0 to 132 and a higher score represents a worse outcome.

    Measured: 12 Weeks Treatment Duration

  3. Change From Baseline to Week 12 in Rett Syndrome Clinician Rating of Hand Function (RTT-HF)

    Clinical assessment of the subject's ability to use their hands for functional purposes (such as reaching for and grasping objects, self-feeding, or drawing). The assessment is made on an 8-point Likert scale (0-7) with 0 denoting normal functioning and 7 the most severe impairment.

    Measured: 12 Weeks Treatment Duration

  4. Change From Baseline to Week 12 in Rett Syndrome Clinician Rating of Ambulation and Gross Motor Skills (RTT-AMB)

    Clinical assessment of the subject's ability to sit, stand, and ambulate (e.g., walking, running, and climbing stairs). The assessment was made on an 8-point Likert scale (0 to 7), with 0 denoting normal functioning and 7 as the most severe impairment.

    Measured: 12 Weeks Treatment Duration

  5. Change From Baseline to Week 12 in Rett Syndrome Clinician Rating of Ability to Communicate Choices (RTT-COMC)

    Clinical assessment of the subject's ability to communicate their choices or preferences, which can include the use of nonverbal means such as eye contact or gestures. The assessment is made on an 8-point Likert scale (0-7) with 0 denoting normal functioning and 7 the most severe impairment.

    Measured: 12 Weeks Treatment Duration

  6. Change From Baseline to Week 12 in Rett Syndrome Clinician Rating of Verbal Communication (RTT-VCOM)

    Clinical assessment of the subject's ability to communicate verbally (e.g. words and phrases). The assessment is made on an 8-point Likert scale (0-7) with 0 denoting normal functioning and 7 the most severe impairment.

    Measured: 12 Weeks Treatment Duration

  7. Change From Baseline to Week 12 in Clinical Global Impression-Severity (CGI-S)

    A 7 point scale that rates the severity of the subject's illness at the time of assessment, relative to the clinician's experience with subjects who have the same diagnosis. A subject is assessed on severity of illness at the time of rating: 1, normal, not at all ill; 2, borderline ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill.

    Measured: 12 Weeks Treatment Duration

  8. Change From Baseline to Week 12 in Rett Syndrome Caregiver Burden Inventory (RTT-CBI) Total Score (Items 1-24)

    The Rett Syndrome Caregiver Burden Inventory (RTT-CBI) scale is intended to directly address caregiver burden and indirectly assess the significance of treatment effects on function in the context of activities of daily living. Ratings are on a 5-point Likert scale including: 0-never; 1-rarely; 2-sometimes; 3-frequently and 4-nearly always. As in the original Caregiver Burden Inventory, the RTT-CBI has 24 negatively worded items (items 1 through 24) yielding a total score up to 96. The RTT-CBI the range is 0 to 96 and a higher score represents a worse outcome.

    Measured: 12 Weeks Treatment Duration

  9. Change From Baseline to Week 12 in Overall Quality of Life Rating of the Impact of Childhood Neurologic Disability Scale (ICND)

    The overall quality of life of the subject is also rated by responding to the following: "Please rate your child's overall 'Quality of Life' on the scale below. Choose the number which you feel is best and circle it." The choices range from 1 ("Poor") to 6 ("Excellent").

    Measured: 12 Weeks Treatment Duration

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted21 Feb 2025
  2. Study start30 Sep 2026 (estimated)
  3. Primary completion30 Sep 2027 (estimated)
  4. Study completion30 Dec 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
Parallel Assignment
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
210 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06840496
Sponsor's protocol ID
BIO-2025R02
Status last verified
Mar 2026
First submitted
17 Feb 2025
Last updated
27 Mar 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
No: We do not plan to make individual participant data (IPD) available to other researchers

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing Bionetide in people with Rett Syndrome, run by Biomed Industries, Inc. at 18 sites in 2 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 9 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 27 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 18 sites in United States, Australia. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact David L Nguyen, PhD (1-800-824-5135, research@biomedind.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Rett Syndrome Behavior Questionnaire (RSBQ) Total Score - Change From Baseline to Week 12 (time frame: Baseline and Week 12). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Mar 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in